CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML



Lucas, Claire M ORCID: 0000-0001-6674-7535, Scott, Laura J, Carmell, Natasha, Holcroft, Alison K, Hills, Robert K, Burnett, Alan K and Clark, Richard E ORCID: 0000-0002-1261-3299
(2018) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2 (9). pp. 964-968.

[img] Text
964.full.pdf - Published version

Download (812kB)

Abstract

PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.

Item Type: Article
Uncontrolled Keywords: Humans, Intracellular Signaling Peptides and Proteins, Carrier Proteins, Membrane Proteins, Nuclear Proteins, Autoantigens, Phosphorylation, Adult, Middle Aged, Female, Male, Proto-Oncogene Proteins c-akt, Leukemia, Myeloid, Acute, Protein Phosphatase 2, Biomarkers, Tumor
Depositing User: Symplectic Admin
Date Deposited: 19 Jul 2018 10:20
Last Modified: 19 Jan 2023 01:30
DOI: 10.1182/bloodadvances.2017013615
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3023905